How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

59,638 results for

HIV Test

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

55581. Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. (Abstract)

Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Adipose tissue from patients with HIV-related lipodystrophy presents a state of chronic inflammation. Altered expression of cytokines/adipokines and macrophage infiltration could be involved in patients' insulin resistance and lipoatrophy. We tested whether antiretrovirals affected adipokine release by human subcutaneous adipocytes and cytokine (...) /chemokine production by human macrophages and examined whether reactive oxygen species (ROS) hyperproduction was related to the effect of antiretrovirals.Differentiated human adipocytes and PMA-THP-1 macrophages were treated with protease inhibitors (PIs: indinavir, nelfinavir, amprenavir, lopinavir, ritonavir and atazanavir) or nucleoside reverse transcriptase inhibitors (NRTIs: stavudine, zidovudine and abacavir) for 24-48 h without or with diphenylene iodonium (DPI), an inhibitor of oxidative stress

2007 Antiviral Therapy

55582. Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Full Text available with Trip Pro

Safety and efficacy of extended-release niacin for the treatment of dyslipidaemia in patients with HIV infection: AIDS Clinical Trials Group Study A5148. Dyslipidaemia is very common in patients with HIV infection, but current therapies are often suboptimal. Since niacin may cause insulin resistance and hepatotoxicity, it has generally been avoided in this setting.Non-diabetic male subjects (n=33) who had well-controlled HIV infection on antiretroviral therapy, fasting triglycerides > or =2.26 (...) model assessment, but insulin resistance measures from the 2-h oral glucose tolerance test only transiently worsened. No subject developed persistent fasting hyperglycaemia; one had persistently elevated 2-h glucose >11.1 mmol/l. There were no significant changes in serum transaminases or uric acid. At week 48, the median change in fasting lipid levels in mmol/l (interquartile range) were: total cholesterol -0.21 (-1.35, -0.05), HDL-C +0.013 (-0.03,+0.28), non-HDL-C -0.49 (-1.37,+0.08

2006 Antiviral Therapy

55583. Low sensitivity of a nested polymerase chain reaction in oropharyngeal washings for the diagnosis of pneumocystis pneumonia in HIV-infected patients. (Abstract)

Low sensitivity of a nested polymerase chain reaction in oropharyngeal washings for the diagnosis of pneumocystis pneumonia in HIV-infected patients. To compare the relative yield and diagnostic utility of the polymerase chain reaction (PCR) analysis for Pneumocystis jirovecii DNA in oropharyngeal washings using transbronchial biopsy (TBBx) and BAL as "gold standards."Prospective study.Academic tertiary center.Oropharyngeal washes were obtained in 50 consecutive patients with clinical (...) pneumocystis pneumonia (PCP). Because of varying clinical severity, not all patients tolerated bronchoscopy. Thirty-five patients underwent TBBx, and 48 patients underwent BAL.DNA extracted from oropharyngeal washings and BAL was subjected to a nested PCR test using primers for the large subunit mitochondrial ribosomal RNA of P jirovecii. Oropharyngeal washings were compared with BAL PCR and TBBx.Sixteen of the 35 TBBx procedures had positive results for PCP (46%). Oropharyngeal washings yielded positive

2005 Chest

55584. Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. (Abstract)

Pulmonary infiltrates in the non-HIV-infected immunocompromised patient: etiologies, diagnostic strategies, and outcomes. Pulmonary complications remain a major cause of both morbidity and mortality in immunocompromised patients. When such individuals present with radiographic infiltrates, the clinician faces a diagnostic challenge. The differential diagnosis in this setting is broad and includes both infectious and noninfectious processes. Rarely are the radiographic findings classic for one (...) of infectious agents even if the procedure is otherwise unrevealing. Third, early use of CT scanning regularly demonstrates lesions missed by plain radiography. Despite these advances, initial therapeutic interventions include the use of broad-spectrum antibiotics and other anti-infectives in order to ensure that the patients is receiving appropriate therapy. With the results of invasive testing, these treatments are then narrowed. Frustratingly, outcomes for immunocompromised patients with infiltrates

2004 Chest

55585. US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. (Abstract)

(timely use of anti-PCP medications, adjunctive corticosteroids), non-HIV-related processes of care (timely use of CAP treatment medications, diagnostic testing, ICU utilization, rates of endotracheal ventilation, placement on respiratory isolation), length of inpatient hospital stay, and inpatient mortality.Rates of timely use of antibiotics and adjunctive corticosteroids for treating PCP were high and improved dramatically from the prior decade. However, compliance with consensus guidelines (...) US hospital care for patients with HIV infection and pneumonia: the role of public, private, and Veterans Affairs hospitals in the early highly active antiretroviral therapy era. We evaluated differences in processes and outcomes of HIV-related pneumonia care among patients in Veterans Affairs (VA), public, and for-profit and not-for-profit private hospitals in the United States. We compared the results of our current study (1995 to 1997) with those of our previous study that included a sample

2004 Chest

55586. HIV-1 infection does not impair human alveolar macrophage phagocytic function unless combined with cigarette smoking. (Abstract)

HIV-1 infection does not impair human alveolar macrophage phagocytic function unless combined with cigarette smoking. Macrophages are an important reservoir for the HIV and contribute to innate lung defense by their ability to phagocytose, digest, and process invading pathogens. We hypothesized that HIV-1 infection may lead to a defect in the phagocytic activity of alveolar macrophages.In order to test this hypothesis, the phagocytic activity of alveolar macrophages from asymptomatic HIV-1 (...) seropositive subjects was compared to healthy seronegative control subjects. Macrophages from one cohort were fed with Escherichia coli and from another cohort with opsonized sheep RBCs (SRBCs), and the phagocytic index was determined at different time intervals.A tertiary-care, urban, university-based referral center.Asymptomatic HIV-1 seropositive subjects and healthy seropositive control subjects recruited from local community.No differences were found in the phagocytic activity between alveolar

2004 Chest

55587. Allergic contact dermatitis to basic red 46 occurring in an HIV-positive patient. (Abstract)

Allergic contact dermatitis to basic red 46 occurring in an HIV-positive patient. A 41-year-old HIV-positive man presented with a 2-month history of a generalized pruritic rash, which had started on his feet. Patch testing made a diagnosis of allergic contact dermatitis to the textile dye basic red 46, likely to have been present in his dark-blue-coloured socks. Complete resolution of his symptoms occurred with avoidance of these socks. The patient had developed allergic contact dermatitis (...) with a low CD4 T lymphocyte count of 361 cells/microl (normal range 410-1545 cells/microl). This raised the question of the level of CD4 count necessary for an individual to develop allergic contact dermatitis to an allergen, given its role in delayed hypersensitivity. It was concluded that a low CD4 count as a result of HIV infection does not decrease the ability of an individual to develop allergic contact dermatitis. Whereas the effector role in delayed type 4 hypersensitivity reactions is mediated

2006 Australasian Journal of Dermatology

55588. Acquisition and clearance of perianal human papillomavirus infection in relation to HIV-positivity in men who have sex with men in the Netherlands. Full Text available with Trip Pro

Acquisition and clearance of perianal human papillomavirus infection in relation to HIV-positivity in men who have sex with men in the Netherlands. This study was performed to establish the prevalence of perianal human papillomavirus (HPV) infection in relation to HIV-positivity in a group of men who have sex with men (MSM), and to correlate follow-up data with regard to acquisition and clearance of HPV infection. Data with regard to HPV prevalence and HIV serostatus during two visits were (...) compared. At both visits participants underwent a routine venereological examination and swabs were taken from the perianal region for HPV DNA testing. During both visits HPV types 16, 18, 31, 33 and 52 were significantly more often detected in HIV-positive individuals. Persistence of HPV type 31 at the perianal region was significantly more often seen in HIV-positive MSM (p=0.036) while the incidence of type 16 may be associated with HIV positivity (p=0.059). In HIV-positive MSM significantly more

2005 Acta Dermato-Venereologica

55589. Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression

Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Empiric Therapy of Helminth Co-infection to Reduce HIV-1 Disease Progression (THE or PHE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00507221 Recruitment Status : Completed First Posted : July 26, 2007 Last Update Posted : November 20, 2014 Sponsor: University of Washington Collaborators: Centers

2007 Clinical Trials

55590. The Effect of Vitamin D and Calcium on Bone in Pediatric HIV

comparing supplementation with oral vitamin D and calcium to placebo. The specific aims of this project are to: Determine the effect of vitamin D and calcium supplementation on bone mineral accrual in HIV-infected children. We hypothesize that BMC and BMD will increase to a greater extent in HIV-infected children who receive supplementation with vitamin D and calcium. This hypothesis will be tested by comparing changes in BMC and BMD, measured by dual energy x-ray absorptiometry (DXA), after one and two (...) supplementation. We will test these hypotheses by comparing longitudinal changes in indices of mineral metabolism and bone turnover markers in HIV-infected children and adolescents receiving vitamin D and calcium supplement versus those receiving placebo Evaluate if vitamin D stores are a determinant of bone mass in HIV infected children and adolescents receiving HAART. We hypothesize that vitamin D stores, as assessed by serum 25-hydroxyvitamin D levels, are an important determinant of bone mass in HIV

2008 Clinical Trials

55591. Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients

Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Study (...) of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients (VK) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00703560 Recruitment Status : Completed First Posted : June 23, 2008 Last Update Posted : January 21, 2013 Sponsor: University of Texas Southwestern Medical Center Information provided

2008 Clinical Trials

55592. Response to Standard HIV Treatment in Bamako, Mali

therapy start day) and 14, and at 1, 3, 6, 9 and 12 months. Patients undergo a medical history, including all confirmed and probably diagnoses made since the previous visit and current status, physical examination and blood tests for CD4 and viral load at each visit. Study start date: July 2008 Condition or disease HIV Infections Detailed Description: This study will assess the efficacy of HIV treatment provided in accordance with the Malian National HIV Treatment Program. The Malian National HIV (...) Update Posted: April 5, 2018 Last Verified: February 24, 2016 Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ): Anti-Retroviral Therapy HIV Virologic Response Treatment Naïve Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic

2008 Clinical Trials

55593. Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

: Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Day 11 [ Time Frame: Baseline (Day 1) and Day 11 ] Change from Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) was calculated as the Day 11 value minus the Baseline value. Blood samples for the measurement of HIV-1 RNA levels were obtained throughout the treatment period (Day 1 to Day 11). Area Under the Plasma Concentration-time Curve From Time Zero (Pre-dose) Extrapolated (...) -ranging study phase IIa integrase inhibitor HIV-1 infection Additional relevant MeSH terms: Layout table for MeSH terms Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Immune System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Dolutegravir Integrase Inhibitors HIV Integrase Inhibitors Enzyme Inhibitors Molecular Mechanisms

2008 Clinical Trials

55594. Effectiveness of Antiretroviral Therapy During Acute HIV Infection

HIV infection as determined by a positive HIV viral load (at least 5,000 copies of RNA per ml of plasma) and a negative or indeterminate Western Blot test Certain laboratory values. More information about this criterion can be found in the protocol. Agrees to use an approved form of contraception Exclusion Criteria: Presence of opportunistic infections or AIDS-defining illnesses, unless they are directly attributable to the acute seroconversion illness Receipt of investigational research agents (...) Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents

2008 Clinical Trials

55595. Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women

for MeSH terms Infection HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Tenofovir Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme (...) to 30 months. Person-years measures the amount of time for each participant, in years, from the date of enrollment to the date of the first HIV-positive test result if HIV-infected during follow-up or to the date of the last HIV-negative test result on follow-up if not HIV-infected during follow-up. Number of HIV-1 Infections of Tenofovir 1% Gel and Vaginal Placebo Gel Arms [ Time Frame: For up to 30 months of follow-up ] Participants were followed for up to 30 months. Participants were tested

2008 Clinical Trials

55596. Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults.

, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine. Planned participation or participation in another experimental protocol during the study period. A family history of congenital or hereditary immunodeficiency. •Any chronic drug therapy, other than HAART or prophylaxis for opportunistic HIV-related infections to be continued during the study period. Vitamins and/or dietary supplements, birth control pills, anti-histamines (...) Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults. Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine in HIV-positive Adults. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2008 Clinical Trials

55597. Family Centered Advanced Care Planning for Adolescents With HIV/AIDS and Their Families

patients have IQ testing results in chart as part of standard of care) Consent from the legal guardian if between ages of 14 and 17 Consent from the surrogate if between ages of 18 and 21 Assent from adolescent aged 14 to 17 Consent from adolescent aged 18 to 21 Legal Guardian Eligibility Criteria (for guardians of adolescents aged 14 to 17): Adolescent is willing to discuss problems related to HIV with him/her Age 21 or older Able to speak English Legal guardian Surrogate Eligibility Criteria (...) , 2015 Last Verified: May 2015 Keywords provided by Maureen Lyon, Children's Research Institute: Quality of Life Adolescent Advance Care Planning Palliative Care End-of-Life Care HIV/AIDS Psychological Adjustment Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

2008 Clinical Trials

55598. Single DermaVir Immunization in HIV-1 Infected Patients on HAART

licensed ELISA test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA On a stable antiretroviral regimen without changes or interruptions for at least 12 weeks prior to study entry Plasma HIV-1 RNA level of less than 50 copies/mL, obtained at least twice within the 12 weeks prior to study entry Peak plasma HIV-1 RNA level before initiation of HAART > 1000 copies/mL CD4 cell count > 300 cells/mm3 within the 12 weeks (...) for additonal information Responsible Party: Genetic Immunity ClinicalTrials.gov Identifier: Other Study ID Numbers: GIHU004 First Posted: July 10, 2008 Results First Posted: March 26, 2013 Last Update Posted: March 26, 2013 Last Verified: February 2013 Keywords provided by Genetic Immunity: HIV Vaccine Immune Therapy DermaVir Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted

2008 Clinical Trials

55599. Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand

, 2015 Last Verified: May 2015 Keywords provided by Assoc.Prof.Jintanat Ananworanich, M.D., South East Asia Research Collaboration with Hawaii: HIV-negative male and female clients ages 18-50 years seeking HIV counseling testing at TRCARC Additional relevant MeSH terms: Layout table for MeSH terms HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune (...) load and CD4 counts assess participant willingness to participate in HIV vaccine efficacy trials and other HIV prevention trials describe volunteer risk behavior Condition or disease HIV Infections Detailed Description: Prospective cohort study of HIV-negative participants who will receive voluntary counseling and testing (VCT) for HIV-antibody in conjunction with questionnaires on risk behavior, willingness to participate in HIV vaccine trials and other HIV prevention trials at 4 month intervals

2008 Clinical Trials

55600. Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1

is a standard-of-care regimen selected by the investigator prior to randomization that is comprised of 2-4 antiretroviral agents. These agents must have been approved by the local regulatory agency or be available through expanded-access programs for treatment of human immunodeficiency virus (HIV). Condition or disease Intervention/treatment Phase HIV Drug: Ibalizumab Phase 2 Detailed Description: The primary objectives of this study are to: Evaluate the dose-response relationship of antiviral activity (...) : Are capable of understanding and have voluntarily signed the informed consent document Have documented HIV-1 infection by official, signed, written history (eg, laboratory report), otherwise an HIV-antibody test will be performed Have no acquired immunodeficiency syndrome (AIDS)-defining events in the 3 months before screening, other than cutaneous Kaposi's sarcoma or wasting syndrome due to HIV Are able and willing to comply with all protocol requirements and procedures Are 18 years of age or older Have

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>